Location History:
- Kornvagen, SE (1992 - 1997)
- Upsala, SE (1995 - 1999)
- Uppsala, SE (1993 - 2000)
Company Filing History:
6 out of 7 
1 out of 8 
1 out of 207 
Years Active: 1992-2000
Title: Kjell Martin Lindberg: Innovator in Biotechnology
Introduction
Kjell Martin Lindberg is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of proteins with binding properties that have implications for vaccine development. With a total of 9 patents to his name, Lindberg's work has advanced our understanding of bacterial interactions and immune responses.
Latest Patents
Among his latest patents, one invention focuses on a fibronectin binding protein. This invention relates to new recombinant DNA molecules comprising nucleotide sequences of *S. dygalactiae* that encode for at least one protein or polypeptide with fibronectin binding properties. Another significant patent involves a bacterial cell surface protein that binds fibronectin, fibrinogen, and collagen. This invention is concerned with a vaccine composition that includes an isolated protein derived from *Staphylococcus aureus*, which has the ability to bind fibronectin. The protein, with a molecular weight of 165,000 daltons, is designed to elicit antibody production, providing protection against *Staphylococcus aureus* bacterial strains in mammals, particularly ruminants.
Career Highlights
Lindberg has worked with prominent companies in the biotechnology sector, including Alfa Laval Agri International Aktiebolag and Alfa Laval Agri International Ab. His career reflects a commitment to advancing biotechnological innovations that address critical health challenges.
Collaborations
Throughout his career, Lindberg has collaborated with esteemed colleagues such as Magnus Hook and Per-Eric Lindgren. These collaborations have contributed to the successful development of his patented technologies.
Conclusion
Kjell Martin Lindberg's contributions to biotechnology through his innovative patents highlight his role as a key inventor in the field. His work continues to influence vaccine development and our understanding of bacterial interactions.